Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

stat rx usa llc - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 5 mg - description methylphenidate hydrochloride usp, is a mild central nervous system (cns) stimulant, available as tablets of 5, 10, and 20 mg for oral administration. methylphenidate hydrochloride is methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is      methylphenidate 5mg structure image methylphenidate hydrochloride usp is a white, odorless, fine crystalline powder. its solutions are acid to litmus. it is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. its molecular formula is c14 h19 no2 •hcl, and its molecular weight is 269.77. inactive ingredients. methylphenidate hydrochloride tablets: colloidal silicon dioxide, compressible sugar, lactose monohydrate and magnesium stearate. additionally, the 5 mg contains fd and c blue #2 and fd and c red #40; the 10 mg contains fd and c blue #2 and d and c yellow #10; and the 20 mg contains fd and c yellow #6. methylphenidate is a mild central nervous system stimula

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

novel laboratories, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 2.5 mg - attention  deficit  disorders , narcolepsy attention  deficit  disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride chewable tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of centra

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

ucb pharma, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - tablet - 5 mg - attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. spec

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

camber pharmaceuticals inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 2.5 mg - attention deficit disorders, narcolepsy attention deficit disorders (previously known as minimal brain dysfunction in children). other terms being used to describe the behavioral syndrome below include: hyperkinetic child syndrome, minimal brain damage, minimal cerebral dysfunction, minor cerebral dysfunction. methylphenidate hydrochloride chewable tablets are indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

adare pharmaceuticals inc - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hcl extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients aged 6 years and older. the effectiveness of dexmethylphenidate hcl extended-release capsules in the treatment of adhd in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting dsm-iv criteria for adhd [see clinical studies (14)]. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/carel

Канада - Енглески - Health Canada

teva canada limited - methylphenidate hydrochloride - tablet (extended-release) - 18mg - methylphenidate hydrochloride 18mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

teva canada limited - methylphenidate hydrochloride - tablet (extended-release) - 27mg - methylphenidate hydrochloride 27mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

teva canada limited - methylphenidate hydrochloride - tablet (extended-release) - 36mg - methylphenidate hydrochloride 36mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

teva canada limited - methylphenidate hydrochloride - tablet (extended-release) - 54mg - methylphenidate hydrochloride 54mg - respiratory and cns stimulants

Канада - Енглески - Health Canada

pharmascience inc - methylphenidate hydrochloride - tablet (extended-release) - 18mg - methylphenidate hydrochloride 18mg - respiratory and cns stimulants